NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
Clinical Trials
90 trialsNCT07481786 2026-04-06
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Sun Yat-sen University
Phase 3 Recruiting
NCT05806060 2026-03-25
BCTOP-T-M01
Fudan University
Phase 3 Recruiting
NCT06580314 2026-03-24
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT04094688 2026-03-03
SOLARIS
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04215731 2026-03-03
FOBEAR
Sun Yat-sen University
Phase 3 Recruiting
NCT06888817 2026-02-25
BRAINS
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT07389265 2026-02-05
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Phase 3 Recruiting
NCT04649489 2026-01-15
TALENTOP
Fudan University
Phase 3 Active not recruiting
NCT06791512 2025-12-24
BASKETâ…¢
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT06733038 2025-12-08
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT07235930 2025-11-19
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
Zhejiang Cancer Hospital
Phase 3 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT01951482 2025-08-17
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Completed
NCT06471465 2025-08-17
BRADI
Institut Cancerologie de l'Ouest
Phase 3 Recruiting
NCT03828227 2025-07-18
COLAGE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Active not recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT06954584 2025-06-24
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital
Phase 3 Recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT05482516 2025-05-22
MRD-GI
Georgetown University
Phase 3 Recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT02891824 2025-02-11
ATALANTE
ARCAGY/ GINECO GROUP
Phase 3 Completed
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT04732598 2025-02-05
AMBITION
Japanese Foundation for Cancer Research
Phase 3 Active not recruiting
NCT01878422 2025-01-31
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Completed
NCT03556839 2025-01-08
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Active not recruiting
NCT04803994 2025-01-07
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Recruiting
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT04687631 2024-12-18
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Recruiting
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT06642844 2024-10-15
PHARBEVACOL
University Hospital, Tours
Phase 3 Not yet recruiting
NCT05271240 2024-09-19
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT06566755 2024-08-22
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Shengjing Hospital
Phase 3 Recruiting
NCT05055908 2024-08-02
BECOME
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT01910610 2024-03-12
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Unknown
NCT01606098 2023-09-13
CAIRO4
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT01303679 2023-09-06
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 3 Terminated
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT05797467 2023-05-24
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT03991403 2023-04-03
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Phase 3 Unknown
NCT00545077 2023-03-31
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT05104281 2023-03-29
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 3 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT02633189 2023-03-24
BEVERLY
National Cancer Institute, Naples
Phase 3 Unknown